FI922579A0 - Fysiologiskt aktiv polypeptidhaltig farmaceutisk komposition. - Google Patents

Fysiologiskt aktiv polypeptidhaltig farmaceutisk komposition.

Info

Publication number
FI922579A0
FI922579A0 FI922579A FI922579A FI922579A0 FI 922579 A0 FI922579 A0 FI 922579A0 FI 922579 A FI922579 A FI 922579A FI 922579 A FI922579 A FI 922579A FI 922579 A0 FI922579 A0 FI 922579A0
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
physiologically active
polypeptic
oral cavity
polypeptide
Prior art date
Application number
FI922579A
Other languages
English (en)
Other versions
FI922579A (fi
FI107704B (fi
Inventor
Shigeyuki Takama
Yukiko Inamoto
Takahiko Wato
Akiya Yamada
Naoki Uchida
Misuzu Kadoriku
Original Assignee
Teikoku Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Seiyaku Kk filed Critical Teikoku Seiyaku Kk
Publication of FI922579A0 publication Critical patent/FI922579A0/fi
Publication of FI922579A publication Critical patent/FI922579A/fi
Application granted granted Critical
Publication of FI107704B publication Critical patent/FI107704B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FI922579A 1991-06-07 1992-06-04 Menetelmä farmaseuttisen seoksen valmistamiseksi, joka sisältää fysiologisesti aktiivista polypeptidiä ja absorbointia edistävää ainetta FI107704B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13646291 1991-06-07
JP13646291 1991-06-07

Publications (3)

Publication Number Publication Date
FI922579A0 true FI922579A0 (fi) 1992-06-04
FI922579A FI922579A (fi) 1992-12-08
FI107704B FI107704B (fi) 2001-09-28

Family

ID=15175681

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922579A FI107704B (fi) 1991-06-07 1992-06-04 Menetelmä farmaseuttisen seoksen valmistamiseksi, joka sisältää fysiologisesti aktiivista polypeptidiä ja absorbointia edistävää ainetta

Country Status (10)

Country Link
US (1) US5929027A (fi)
EP (1) EP0517211B1 (fi)
AT (1) ATE276767T1 (fi)
AU (1) AU653026B2 (fi)
CA (1) CA2070061C (fi)
DE (1) DE69233413T2 (fi)
ES (1) ES2229203T3 (fi)
FI (1) FI107704B (fi)
NO (1) NO307772B1 (fi)
SG (1) SG43858A1 (fi)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US6344213B1 (en) 1996-03-29 2002-02-05 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6610329B2 (en) 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
JP3628713B2 (ja) * 1993-06-07 2005-03-16 帝國製薬株式会社 生理学的に活性なペプチドを含有する膣投与製剤
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
FR2735131B1 (fr) * 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO1997047288A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
US6391303B1 (en) 1996-11-18 2002-05-21 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2288968A1 (en) * 1997-04-14 1998-10-22 Takashi Yazaki Permucous preparation
EP0880969A1 (en) 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
DE69920711D1 (de) * 1998-07-21 2004-11-04 Monsanto Technology Llc Klärung von protein-niederschlagsuspensionen durch verwendung von anionischen polymerischen flockungsmitteln
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
CA2338358C (en) 1998-07-27 2009-04-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
KR100659753B1 (ko) 1998-08-07 2006-12-20 에미스페어 테크놀로지스, 인코포레이티드 활성제 전달용 화합물 및 조성물
WO2000025598A1 (en) * 1998-11-03 2000-05-11 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
JP2002537321A (ja) * 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ATE288415T1 (de) 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
EP1808438B1 (en) * 1999-06-29 2014-10-01 MannKind Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
DE60038183T2 (de) 1999-12-16 2009-02-19 Emisphere Technologies, Inc. Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
CA2446619C (en) 2001-05-11 2011-04-26 Elan Corporation, Plc Permeation enhancers
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
WO2003094886A2 (en) * 2002-05-07 2003-11-20 Ferring Bv Desmopressin in an orodispersible dosage form
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
GB0221712D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods of treatment
WO2004052405A1 (en) * 2002-12-11 2004-06-24 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
BRPI0302736B8 (pt) * 2003-06-02 2021-05-25 Ems S/A composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
EP1530967B1 (en) 2003-11-13 2006-05-03 Ferring B.V. Blister pack and solid dosage form comprising desmopressin
EP1708738B1 (en) * 2004-01-12 2016-05-04 MannKind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
CA2553392A1 (en) * 2004-01-16 2005-08-11 Biodel Inc Sublingual drug delivery device
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
PT2319500E (pt) * 2004-03-12 2013-01-23 Biodel Inc Composições de distribuição de fármacos de actuação rápida
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
KR101273120B1 (ko) 2004-08-20 2013-06-13 맨카인드 코포레이션 다이케토피페라진 합성의 촉매 작용
ES2540886T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
NZ564789A (en) * 2005-07-22 2010-07-30 Myriad Genetics Inc High drug load formulations and dosage forms
US8466104B2 (en) * 2005-08-26 2013-06-18 Abbvie Inc. Therapeutically active alpha MSH analogues
CN104324366B (zh) 2005-09-14 2016-10-05 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
EP2012817A2 (en) * 2006-04-12 2009-01-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
AU2009244797B2 (en) 2008-05-07 2015-01-22 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
PT3225249T (pt) 2008-05-21 2019-01-17 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono não perturbado pela nocturia
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US20110229565A1 (en) 2008-09-17 2011-09-22 Karp Jeffrey M Drug Delivery Composition Comprising a Self-Assembled Gelator
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
SG176738A1 (en) 2009-06-12 2012-01-30 Mannkind Corp Diketopiperazine microparticles with defined specific surface areas
KR101792696B1 (ko) 2009-06-18 2017-11-02 알레간 인코포레이티드 안전한 데스모프레신 투여
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP2512454A2 (en) 2009-12-16 2012-10-24 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP4079292A1 (en) 2010-09-24 2022-10-26 The Brigham and Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX361757B (es) 2011-09-19 2018-12-13 Orexo Ab Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides.
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CN107427469B (zh) 2015-01-12 2021-01-26 安特里斯生物制药公司 固体口服剂型
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
US9962339B2 (en) 2015-10-08 2018-05-08 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
EP3452094B1 (en) * 2016-05-06 2021-11-17 The Brigham and Women's Hospital, Inc. Binary self assembled gels for controlled delivery of encapsulated agents to cartilage
CA3032823A1 (en) 2016-08-05 2018-02-08 Taurus Development Company Llc Room temperature stable oral calcitonin formulation
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
US10881745B2 (en) 2017-05-08 2021-01-05 Alivio Therapeutics, Inc. Formulation of nanostructured gels for increased agent loading and adhesion
WO2019102310A1 (en) * 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions
EP3863602A1 (en) 2018-10-11 2021-08-18 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
JPS57128634A (en) * 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
JPH01139528A (ja) * 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5204327A (en) * 1988-11-18 1993-04-20 Ashi Kasei Kogyo Kabushiki Kaisha Treatment of cerebral edema with anp pharmaceutical compositions
DK0585355T3 (da) * 1991-05-20 1995-06-06 Tanabe Seiyaku Co Flerlagspræparat med reguleret frigivelse
IL99666A (en) * 1991-10-07 1996-09-12 Yeda Res & Dev Vanadyl complexes of hydroxamate chelators and pharmaceutical compositions comprising them
CA2094217A1 (en) * 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition

Also Published As

Publication number Publication date
AU653026B2 (en) 1994-09-15
NO922232L (no) 1992-12-08
DE69233413D1 (de) 2004-10-28
NO922232D0 (no) 1992-06-05
DE69233413T2 (de) 2006-02-02
ES2229203T3 (es) 2005-04-16
CA2070061A1 (en) 1992-12-08
ATE276767T1 (de) 2004-10-15
NO307772B1 (no) 2000-05-29
EP0517211B1 (en) 2004-09-22
EP0517211A1 (en) 1992-12-09
SG43858A1 (en) 1997-11-14
AU1726492A (en) 1992-12-10
CA2070061C (en) 2004-02-10
FI922579A (fi) 1992-12-08
US5929027A (en) 1999-07-27
FI107704B (fi) 2001-09-28

Similar Documents

Publication Publication Date Title
FI922579A0 (fi) Fysiologiskt aktiv polypeptidhaltig farmaceutisk komposition.
NO174412C (no) Fremgangsmåte for fremstilling av en farmasöytisk formulering med programmert frigjöring for oral anvendelse
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
EP0009609A3 (en) Adjuvant for promoting absorption of therapeutically active substances through the digestive tract, pharmaceutical composition comprising said adjuvant and process for preparing said pharmaceutical composition; enamine derivatives
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
DE69210879D1 (de) Gellanester
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
DE3869010D1 (de) Miocamycin enthaltende pharmazeutische zusammensetzungen fuer die topische anwendung.
US4436732A (en) Medicated compound for treating diseases infected by virus of the herpes group
ES2038658T3 (es) Una formulacion farmaceutica conteniendo indometacina.
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
JPS57144214A (en) Pharmaceutical preparation for rectum medication
DE3689254D1 (de) Arzneimittel auf Dextrorphanbasis zur intranasalen Applikation.
ATE15139T1 (de) Phosphonomycine pharmazeutische zusammensetzung in tablettenform.
EP0367509A3 (en) Formulations
DK493887A (da) Buccal formulering
IT1236834B (it) Complessi del 4-idrossi-2-metil-n--2-piridinil-2-h,2-benzotiazina-3- carbossiammide-1,1-diossido con cilodestrine, aventi azione anti- infiammatoria, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1203815B (it) Esteri polisaccaridici e loro sali
RU95110776A (ru) Композиция для лечения осложнений диабета, применение 6-десатурированной н-6 жирной кислоты для лечения осложнений сахарного диабета, способ получения лекарственного средства, аскорбатный эфир 6-десатурированной н-6 эссенциальной жирной кислоты, его применение
RU94001686A (ru) Иммуномодулирующее лекарственное средство

Legal Events

Date Code Title Description
MA Patent expired